You are here
2018 EUROPEAN SOCIETY FOR MEDICAL ONCOLOGY (ESMO) ANNUAL MEETING
PLEASE NOTE: All assets on this page are intended for use by media professionals.
At Pfizer Oncology, we are committed to advancing medicines wherever we believe we can make a meaningful difference on the lives of patients. Today, Pfizer Oncology has an industry-leading portfolio of 12 approved cancer medicines across 19 indications, including breast, prostate, kidney, lung and hematology. We also have one of the deepest oncology biosimilars pipelines, with two medicines approved globally and several assets in mid to late-stage development for the treatment of cancer or as supportive care. Pfizer Oncology is striving to change the trajectory of cancer.
For the latest information on our growing pipeline, product portfolio and collaborations with the broader cancer community, visit this page periodically for leadership perspective, fact sheets, videos and other media resources. We also encourage you to visit our other online resources for additional information on Pfizer Oncology.
PFIZER AT ESMO
Pfizer Oncology will be highlighting its diverse and enterprising oncology portfolio at this year’s ESMO Conference, with more than 30 company-sponsored abstracts spanning 11 of its marketed therapies and investigational compounds across eight solid tumors. The data being presented reinforces Pfizer’s continued commitment to develop new medicines and explore novel targets and combinations that strive to change the trajectory of cancer.
Please visit the link below for information on Pfizer Oncology being showcased at ESMO.
Pfizer Oncology Data Presentations at the ESMO Annual Meeting 2018
CHANGING THE TRAJECTORY OF CANCER TAKES FOCUS – AT SCALE
Andy Schmeltz, Global President and General Manager, Pfizer Oncology
MAPPING THE FUTURE ONCOLOGY LANDSCAPE: HOW WE CAN BUILD UPON IMMUNO-ONCOLOGY
Chris Boshoff, MD, PhD, Senior Vice President and Head of Immuno-Oncology, Translational Oncology and Early Development